cabozantinib,nivolumab
exelixis,bms
['9er', 'nivo', 'nivolumab', 'improve', 'cabozantinib', 'rcc,(-irccs),(-srcc),(-urcc)']
#asco22 deeper orr correlated with improved pfs and os in phase 3 checkmate 9er trial with cabozantinib plus nivolumab in mrcc #kidneycancer #ascodailynews : pertinent data for counseling during rx. 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E